2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
685
Carcinoma, Non-Small-Cell Lung
328
Neoplasms
170
Breast Neoplasms
166
Lung Neoplasms
158
Urinary Bladder Neoplasms
157
Neoplasm Metastasis
140
Cholangiocarcinoma
113
Ovarian Neoplasms
106
Biliary Tract Neoplasms
95
Lymphoma, Large B-Cell, Diffuse
73
Nasopharyngeal Carcinoma
71
Lymphoma
66
Sarcoma
63
Recurrence
62
Gallbladder Neoplasms
61
Carcinoma, Transitional Cell
56
Triple Negative Breast Neoplasms
54
Hodgkin Disease
52
Colorectal Neoplasms
49
Lymphoma, Non-Hodgkin
48
Fallopian Tube Neoplasms
48
Adenocarcinoma
45
Bile Duct Neoplasms
40
Carcinoma, Ovarian Epithelial
31
Non-Muscle Invasive Bladder Neoplasms
30
Uterine Cervical Neoplasms
28
Carcinoma
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Adenocarcinoma of Lung
27
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
Oncolytic Virotherapy
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Bevacizumab
2
valrubicin
1
thymoglobulin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Tenofovir
1
Rituximab
1
Radiotherapy, Intensity-Modulated
1
Papillomavirus Vaccines
1
Nimorazole
1
Mitomycin
1
Lamivudine
1
Kidney Transplantation
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Gemcitabine
1
Gels
1
Fluorescent Antibody Technique
1
Drug Therapy
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Virus Diseases
×
Gemcitabine
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled